CBD also modulates other receptors in the body. For instance, modulation of the 5-HT1A receptor (involved with serotonin, a mood hormone) provides mood-balancing properties: It’s calming, but not highly sedating, so it’s considered neutral — though it often results in improved sleep for many people. Another example is modulation of opioid receptors, which provides pain relief and tissue-supporting properties.
This is a critical area for new research. While there is preliminary evidence that CBD may have therapeutic value for a number of conditions, we need to be careful to not get ahead of the evidence. Ninety-five percent of drugs that move from promising preclinical findings to clinical research do not make it to market. The recently announced elimination of the PHS review of non-federally funded research protocols involving marijuana is an important first step to enhance conducting research on marijuana and its components such as CBD. Still, it is important to try to understand the reasons for the lack of well-controlled clinical trials of CBD including: the regulatory requirements associated with doing research with Schedule I substances, including a requirement to demonstrate institutional review board approval; and the lack of CBD that has been produced under the guidance of Current Good Manufacturing Processes (cGMP) – required for testing in human clinical trials – available for researchers. Furthermore, the opportunity to gather important information on clinical outcomes through practical (non-randomized) trials for patients using CBD products available in state marijuana dispensaries is complicated by the variable quality and purity of CBD from these sources.
From a pharmacological perspective, Cannabis' (and CBD's) diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . Cannabinoid receptors are utilized endogenously by the body through the endocannabinoid system, which includes a group of lipid proteins, enzymes, and receptors that are involved in many physiological processes. Through its modulation of neurotransmitter release, the endocannabinoid system regulates cognition, pain sensation, appetite, memory, sleep, immune function, and mood among many other bodily systems. These effects are largely mediated through two members of the G-protein coupled receptor family, cannabinoid receptors 1 and 2 (CB1 and CB2)[12, 8]. CB1 receptors are found in both the central and peripheral nervous systems, with the majority of receptors localized to the hippocampus and amygdala of the brain. Physiological effects of using cannabis make sense in the context of its receptor activity as the hippocampus and amygdala are primarily involved with regulation of memory, fear, and emotion. In contrast, CB2 receptors are mainly found peripherally in immune cells, lymphoid tissue, and peripheral nerve terminals .
Since I've been using CBD, my mood has been significantly elevated and stable, although I understand my experience proves nothing. The placebo effect can be strong, especially for health symptoms modulated by the brain. Cooper encouraged me to continue talking with my doctor because "these powerful stories, as well as evidence from preclinical or animal studies, help drive the basis for rigorous studies."
About 40 percent of the 84 items were "under-labeled," meaning they had significantly more CBD than indicated. In addition, approximately a quarter were "over-labeled," meaning consumers not only are paying good money for an ingredient they are not getting but also may not be getting a large enough dose to achieve any potential therapeutic benefit. More concerning, Bonn-Miller says, is that some CBD products may contain THC in amounts that could make you intoxicated or impaired